Dihydroartemisinin is a hypoxia active anticancer drug

被引：2
|
作者：
Ontikatze, T. [1 ]
Handrick, R. [1 ]
Grimm, F. [1 ]
Henke, G. [2 ]
Daniel, P. T. [3 ]
Belka, C. [2 ]
Jendrossek, V. [1 ]
机构：
[1] Univ Hosp Duisburg Essen, Essen, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Univ Med Berlin, Berlin, Germany
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 05期
关键词：
D O I：
10.1016/S1359-6349(10)71170-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [41] Supramolecular hybrids of carbon dots and dihydroartemisinin for enhanced anticancer activity and mechanism analysis
    Li, Yawei
    Shi, Nianqiu
    Zhang, Wei
    Zhang, Hong
    Song, Yu
    Zhu, Wenhe
    Feng, Xianmin
    JOURNAL OF MATERIALS CHEMISTRY B, 2020, 8 (42) : 9777 - 9784
  • [42] Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy
    Xie, Zhiqi
    Guo, Wangwei
    Guo, Ningning
    Huangfu, Mingyi
    Liu, Huina
    Lin, Mengting
    Xu, WenHong
    Chen, Jiejian
    Wang, TianTian
    Wei, Qichun
    Han, Min
    Gao, Jianqing
    ACTA BIOMATERIALIA, 2018, 71 : 351 - 362
  • [43] Anticancer efficacy of the hypoxia-activated pro-drug evofosfamide in prcelinIcal osteosarcoma murine models
    Liapis, Vasilios
    Labrinidis, Agatha
    Zinonos, Irene
    Hay, Shelley
    Ponomarev, Vladimir
    Panagopoulos, Vasilios
    DeNichilo, Mark
    Ingman, Wendy
    Atkins, Gerald J.
    Findlay, David M.
    Evdokiou, Andreas
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S59 - S59
  • [44] Electrochemical and DFT study of an anticancer and active anthelmintic drug at carbon nanostructured modified electrode
    Ghalkhani, Masoumeh
    Beheshtian, Javad
    Salehi, Maryam
    MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2016, 69 : 1345 - 1353
  • [45] TARGETED ANTICANCER CHEMOTHERAPY WITH MICROENCAPSULATED ANTICANCER DRUG
    KATO, T
    MEMOTO, R
    ARTIFICIAL ORGANS, 1984, 8 (02) : 243 - 243
  • [46] Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs
    Galmarini, Carlos M.
    Warren, Galya
    Senanayake, Madapathage T.
    Vinogradov, Serguei V.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 395 (1-2) : 281 - 289
  • [47] THE ACTIVE METABOLITE HYDROXYTAMOXIFEN OF THE ANTICANCER DRUG TAMOXIFEN INDUCES STRUCTURAL-CHANGES IN MEMBRANES
    CUSTODIO, JBA
    ALMEIDA, LM
    MADEIRA, VMC
    BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1153 (02) : 308 - 314
  • [48] BIS(ACETATO)AMMINEDICHLORO(CYCLOHEXYLAMINE)PLATINUM(IV), AN ORALLY-ACTIVE ANTICANCER DRUG
    NEIDLE, S
    SNOOK, CF
    MURRER, BA
    BARNARD, CFJ
    ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1995, 51 : 822 - 824
  • [49] NCI's anticancer drug screening program may not be selecting for clinically active compounds
    Brown, JM
    ONCOLOGY RESEARCH, 1997, 9 (05) : 213 - 215
  • [50] Anticancer Drug Development
    P Loadman
    British Journal of Cancer, 2002, 86 (10) : 1665 - 1666
12345